ArticleVeterinary research2025
Highly suitable LFBK cells for African swine fever virus replication and type I interferon-induced immune studies.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
African swine fever virus (ASFV), the causative agent of African swine fever, is a fatal haemorrhagic virus affecting domestic pigs and wild boars. The primary target cells for ASFV infection are porcine alveolar macrophages (PAMs); however, PAM isolation and maintenance are technically challenging, and genetic manipulation of these cells is difficult. The lack of suitable cell lines that support ASFV infection and replication has significantly hindered vaccine development. This study aimed to overcome these limitations and advance ASFV research. The results demonstrate that the foetal porcine kidney cells (LFBK) are suitable for ASFV studies. We observed that ASFV replicated significantly more efficiently in LFBK cells than in PAMs. Furthermore, LFBK cells exhibited antiviral immune responses similar to PAMs following ASFV infection or DNA analog. These findings suggest that the LFBK cell line could provide a much-needed platform for studying ASFV replication and pathogenesis while serving as a valuable tool for understanding ASFV-induced immune mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.